Skip to main content

Are you Dr. Nejadnik?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

  • Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
    You already have 27 invites waiting!
  • Read the latest clinical news, personalized to your specialty.

Claim this profile

Not you? Find your profile

  • Office

    1295 Ustilago Dr
    San Ramon, CA 94582
    Phone+1 925-234-0313

Summary

  • Dr. Bijan Nejadnik, MD is a gastroenterologist in San Ramon, California. He is currently licensed to practice medicine in California and Colorado.

Education & Training

  • Johns Hopkins University
    Johns Hopkins UniversityFellowship, Gastroenterology, 2002 - 2005
  • Oregon Health & Science University (OHSU Health)
    Oregon Health & Science University (OHSU Health)Residency, Internal Medicine, 1994 - 1996
  • Cook County Health and Hospitals System
    Cook County Health and Hospitals SystemInternship, Internal Medicine, 1993 - 1994
  • University Cath De Louvain
    University Cath De LouvainClass of 1991

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 1998 - 2026
  • CO State Medical License
    CO State Medical License 2008 - 2019

Publications & Presentations

PubMed

Press Mentions

  • SanBio Announces Publication Comparing Outcome Measures for Persons with Chronic Traumatic Brain Injury in Expert Review of Neurotherapeutics
    SanBio Announces Publication Comparing Outcome Measures for Persons with Chronic Traumatic Brain Injury in Expert Review of NeurotherapeuticsNovember 1st, 2021
  • Bijan Nejadnik, M.D., Appointed as Chief Medical Officer of SanBio
    Bijan Nejadnik, M.D., Appointed as Chief Medical Officer of SanBioMay 15th, 2019
  • Galena Biopharma Presents Positive Interim Safety Data on the NeuVax™ (Nelipepimut-S) Clinical Trial in Combination with Trastuzumab in High-Risk HER2 3+ Patients at the AACR Annual Meeting 2017
    Galena Biopharma Presents Positive Interim Safety Data on the NeuVax™ (Nelipepimut-S) Clinical Trial in Combination with Trastuzumab in High-Risk HER2 3+ Patients at the AACR Annual Meeting 2017April 4th, 2017
  • Join now to see all